Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin S Murnane

Showing results (31-40 of 81) with videos related to

Pageof 9
Sort By:
Biochemical Pharmacology|January 8, 2026
Agonism of FFA4/GPR120 activates tyrosine hydroxylase and confers neuroprotection from 6-OHDA-induced cytotoxicity in PC12 cells and in a rat 6-OHDA model of Parkinson's diseaseFarnoosh Moghaddam, Monika Binwal, Andrea J Green, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
Impacts of Self-Administered 3,4-Methylenedioxypyrovalerone (MDPV) Alone, and in Combination with Caffeine, on Recognition Memory and Striatal Monoamine Neurochemistry in Male Sprague-Dawley Rats: Comparisons with Methamphetamine and CocaineRobert W Seaman, Kariann Lamon, Nicholas Whitton, et al.
Brain Sciences|March 28, 2024
Impacts of Self-Administered 3,4-Methylenedioxypyrovalerone (MDPV) Alone, and in Combination with Caffeine, on Recognition Memory and Striatal Monoamine Neurochemistry in Male Sprague Dawley Rats: Comparisons with Methamphetamine and CocaineRobert W Seaman, Kariann Lamon, Nicholas Whitton, et al.
Cureus|December 22, 2025
Development and Administration of a Skin Survey Questionnaire for Methamphetamine UsersBrynne E Tynes, Kevin S Murnane, Mary F Vest, et al.
Behavioural Pharmacology|June 19, 2019
Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in ratsWilliam S Hyatt, Michael D Berquist, Neha M Chitre, et al.
Frontiers in Psychiatry|March 31, 2023
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorderJonathan Brett, Elizabeth Knock, P Todd Korthuis, et al.
Behavioural Pharmacology|February 27, 2020
The synthetic cathinone 3,4-methylenedioxypyrovalerone increases impulsive action in ratsWilliam S Hyatt, Caitlin E Hirsh, Lauren N Russell, et al.
Frontiers in Psychiatry|November 29, 2023
Immunotherapeutic treatment of inflammation in mice exposed to methamphetamineJennifer M Loftis, Sankrith Ramani, Evan J Firsick, et al.
Epilepsia|October 11, 2025
Nanoparticle-encapsulated neuropeptide Y provides robust seizure protection in SCN1A-derived epilepsySamantha L Reed, Lauren M Aiani, Eesha Faiz, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|December 7, 2020
Examination of xylene exposure in the U.S. Population through biomonitoring: NHANES 2005-2006, 2011-2016Víctor R De Jesús, Daniel F Milan, Young M Yoo, et al.
Pageof 9

Showing results (31-40 of 81) with videos related to

Sort By:
Pageof 9
Biochemical Pharmacology|January 8, 2026
Agonism of FFA4/GPR120 activates tyrosine hydroxylase and confers neuroprotection from 6-OHDA-induced cytotoxicity in PC12 cells and in a rat 6-OHDA model of Parkinson's diseaseFarnoosh Moghaddam, Monika Binwal, Andrea J Green, et al.
Biorxiv : the Preprint Server for Biology|February 14, 2024
Impacts of Self-Administered 3,4-Methylenedioxypyrovalerone (MDPV) Alone, and in Combination with Caffeine, on Recognition Memory and Striatal Monoamine Neurochemistry in Male Sprague-Dawley Rats: Comparisons with Methamphetamine and CocaineRobert W Seaman, Kariann Lamon, Nicholas Whitton, et al.
Brain Sciences|March 28, 2024
Impacts of Self-Administered 3,4-Methylenedioxypyrovalerone (MDPV) Alone, and in Combination with Caffeine, on Recognition Memory and Striatal Monoamine Neurochemistry in Male Sprague Dawley Rats: Comparisons with Methamphetamine and CocaineRobert W Seaman, Kariann Lamon, Nicholas Whitton, et al.
Cureus|December 22, 2025
Development and Administration of a Skin Survey Questionnaire for Methamphetamine UsersBrynne E Tynes, Kevin S Murnane, Mary F Vest, et al.
Behavioural Pharmacology|June 19, 2019
Repeated administration of synthetic cathinone 3,4-methylenedioxypyrovalerone persistently increases impulsive choice in ratsWilliam S Hyatt, Michael D Berquist, Neha M Chitre, et al.
Frontiers in Psychiatry|March 31, 2023
Exploring psilocybin-assisted psychotherapy in the treatment of methamphetamine use disorderJonathan Brett, Elizabeth Knock, P Todd Korthuis, et al.
Behavioural Pharmacology|February 27, 2020
The synthetic cathinone 3,4-methylenedioxypyrovalerone increases impulsive action in ratsWilliam S Hyatt, Caitlin E Hirsh, Lauren N Russell, et al.
Frontiers in Psychiatry|November 29, 2023
Immunotherapeutic treatment of inflammation in mice exposed to methamphetamineJennifer M Loftis, Sankrith Ramani, Evan J Firsick, et al.
Epilepsia|October 11, 2025
Nanoparticle-encapsulated neuropeptide Y provides robust seizure protection in SCN1A-derived epilepsySamantha L Reed, Lauren M Aiani, Eesha Faiz, et al.
Biomarkers : Biochemical Indicators of Exposure, Response, and Susceptibility to Chemicals|December 7, 2020
Examination of xylene exposure in the U.S. Population through biomonitoring: NHANES 2005-2006, 2011-2016Víctor R De Jesús, Daniel F Milan, Young M Yoo, et al.
Pageof 9